

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1-26. (canceled)

27. (currently amended) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody wherein said antibody is raised against a protofibril comprising an A β -Arc peptide ~~comprising a mutation Glu₂₂-Gly₂₂ selected from the group consisting of~~ A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A β 40-Arc (Amino Acids 1-40 of SEQ ID NO: 1), and A β 42-Arc (SEQ ID NO: 1).

28-31. (canceled)

32. (previously presented) The method according to claim 27, wherein said antibody is monoclonal.

33. (previously presented) The method according to claim 27, wherein said antibody is human or humanized.

34-43. (canceled)

44. (previously presented) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a protofibril comprising an A β -Arc

peptide selected from the group consisting of A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A β 40-Arc (Amino Acids 1-40 of SEQ ID NO:1), A β 41-Arc (Amino Acids 1-41 of SEQ ID NO:1), A β 42-Arc (SEQ ID NO:1), and combinations thereof.

45. (previously presented) The method according to claim 44, wherein said protofibril further comprises an A β peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.

46-47. (cancelled)

48. (previously presented) The method according to claim 27, wherein said protofibril further comprises an A β peptide with a mutation selected from the group consisting of the Dutch, Flemish, Italian and Iowa mutations.

49. (previously presented) The method according to claim 44, wherein said antibody is monoclonal.

50. (previously presented) The method according to claim 44, wherein said antibody is human or humanized.

51. (previously presented) A method for the prevention or treatment of Alzheimer's disease (AD) in a subject having or suspected of having AD, comprising administering to said subject a therapeutically effective amount of an antibody, wherein said antibody is raised against a composition comprising an A β -Arc peptide selected from the group consisting of A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1), A β 40-Arc (Amino Acids 1-40 of SEQ ID

NO:1), A β 41-Arc (Amino Acids 1-41 of SEQ ID NO:1), A β 42-Arc (SEQ ID NO:1), and combinations thereof.

52. (currently amended) The method according to claim 44, wherein said ~~composition~~ protofibril further comprises an A β peptide having a mutation selected from the group consisting of the Dutch, Flemish, Italian, Iowa mutations, and combinations thereof.

53. (previously presented) The method according to claim 27, wherein said A β -Arc peptide is A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

54. (previously presented) The method according to claim 27, wherein said A β -Arc peptide is A β 40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

55. (previously presented) The method according to claim 27, wherein said A β -Arc peptide is A β 41-Arc (Amino Acids 1-41 of SEQ ID NO:1).

56. (previously presented) The method according to claim 27, wherein said A β -Arc peptide is A β 42-Arc (SEQ ID NO:1).

57. (previously presented) The method according to claim 44, wherein said A β -Arc peptide is A β 39-Arc (Amino Acids 1-39 of SEQ ID NO:1).

58. (previously presented) The method according to claim 44, wherein said A β -Arc peptide is A β 40-Arc (Amino Acids 1-40 of SEQ ID NO:1).

59. (previously presented) The method according to claim 44, wherein said A β -Arc peptide is A β 41-Arc (Amino Acids 1-41 of SEQ ID NO:1).

60. (previously presented) The method according to claim 44, wherein said A β -Arc peptide is A β 42-Arc (SEQ ID NO:1).